The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | Phase Ib/II study of maplirpacept, tafasitamab, and lenalidomide in transplant-ineligible R/R DLBCL
In this interview, Adam Olszewski, MD, Brown University, Providence, RI, discusses the Phase Ib/II study (NCT05626322) of maplirpacept, tafasitamab, and lenalidomide in transplant-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Despite encouraging results, the study was terminated early. However, Dr Olszewski notes that maplirpacept is undergoing further development in DLBCL in combination with glofitamab, an approach that may stimulate both adaptive and innate immunity. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We are very happy to be participating in the study of maplirpacept with lenalidomide and tafasitamab for relapsed diffuse large B-cell lymphoma. There has been a huge interest in activating innate immunity, particularly with macrophages in diffuse large B-cell lymphoma. and maplirpacept is an agent that blocks SIRP-alpha, which is a molecule in this pathway, but blocking it actually does not cause anemia, which was a problem with prior CD47 blocking agents...
We are very happy to be participating in the study of maplirpacept with lenalidomide and tafasitamab for relapsed diffuse large B-cell lymphoma. There has been a huge interest in activating innate immunity, particularly with macrophages in diffuse large B-cell lymphoma. and maplirpacept is an agent that blocks SIRP-alpha, which is a molecule in this pathway, but blocking it actually does not cause anemia, which was a problem with prior CD47 blocking agents. The study was terminated early, despite fairly good results, with I think about half of patients attaining complete response, but the treatment was quite manageable without any major toxicity seen related to maplirpacept. So I believe that this drug and the overall concept of activating innate immunity has still a significant role for diffuse B-cell lymphoma. And maplirpacept is still being developed in combination with glofitamab, which may be an interesting partner to combine the adaptive and innate immunity as a stimulation to treat relapsed diffuse large B-cell lymphoma. So this is also a very interesting avenue of research, which I’m hoping we’ll see a lot about coming in the coming years.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
